Table 2.
Effect of delta MMPs/TIMPs ratio on sICH, relevant HT, death, and TACS adjusting for major determinants.
| MMP/TIMP | sICHa OR (95% CI) |
p | Relevant HTa OR (95% CI) |
p | Deatha OR (95% CI) |
p | TACSb OR (95% CI) |
p |
|---|---|---|---|---|---|---|---|---|
| MMP9/TIMP1 | 1.67 (1.17–2.38) | 0.005 | 1.74 (1.17–2.57) | 0.006 | 1.22 (0.92–1.63) | 0.171 | 1.15 (0.93–1.42) | 0.211 |
| MMP1/TIMP1 | 1.01 (0.96–1.06) | 0.704 | 1.01 (0.96–1.07) | 0.615 | 0.97 (0.86–1.08) | 0.554 | 1.02 (0.99–1.06) | 0.260 |
| MMP2/TIMP1 | 0.99 (0.81–1.21) | 0.923 | 1.05 (0.86–1.29) | 0.626 | 1.37 (1.00–1.87) | 0.048 | 1.38 (1.06–1.80) | 0.016 |
| MMP3/TIMP1 | 0.85 (0.59–1.24) | 0.404 | 0.88 (0.55–1.39) | 0.579 | 1.00 (0.53–1.88) | 0.991 | 1.06 (0.86–1.32) | 0.587 |
| MMP7/TIMP1 | 1.05 (0.97–1.13) | 0.273 | 1.04 (0.96–1.13) | 0.331 | 1.01 (0.92–1.11) | 0.884 | 1.00 (0.94–1.07) | 0.943 |
| MMP8/TIMP1 | 0.99 (0.92–1.06) | 0.788 | 1.00 (0.94–1.06) | 0.889 | 1.00 (0.97–1.03) | 0.730 | 1.01 (0.99–1.03) | 0.585 |
| MMP9/TIMP2 | 1.74 (1.21–2.49) | 0.003 | 1.71 (1.16–2.52) | 0.007 | 1.43 (1.02–1.99) | 0.037 | 1.35 (1.03–1.78) | 0.032 |
| MMP2/TIMP2 | 0.99 (0.85–1.16) | 0.912 | 1.04 (0.88–1.22) | 0.652 | 1.27 (0.96–1.68) | 0.098 | 1.38 (1.08–1.76) | 0.009 |
| MMP2/TIMP4 | 0.90 (0.68–1.19) | 0.458 | 0.98 (0.75–1.27) | 0.877 | 1.61 (1.10–2.36) | 0.015 | 1.37 (1.05–1.77) | 0.019 |
Bold font indicates statistically significant data.
MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; OR, odds ratio; CI, confidence interval; sICH, symptomatic intracerebral hemorrhage; relevant HT, relevant hemorrhagic transformation; TACS, total anterior circulation syndrome.
aBinary logistic regression analysis adjustment for age, sex, onset-to-treatment time, baseline blood glucose, baseline NIHSS, history of atrial fibrillation, history of congestive heart failure, center effect, history of recent infection/inflammation, statin use, aspirin use, antiplatelet use, and antihypertensive use.
bBinary logistic regression analysis adjustment for age, sex, onset-to-treatment time, history of recent infection/inflammation, history of atrial fibrillation, history of hypertension, history of diabetes, history of congestive heart failure, statin use, aspirin use, other antiplatelet use, antihypertensive use, and center effect.